JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

Strona główna・Stock List・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Closed

4.05 -1.94

Buy Sell

Overview

Share price change

24h

Current

Min

4.01

Max

4.13

Key metrics
By Trading Economics
Income	466K -27M
Sales	2M 15M
Profit margin	-178.834
Employees	141
EBITDA	-2M -29M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+256.07% upside

Dividends
By Dow Jones
Next Earnings	4 maj 2026

Market Stats
By TradingEconomics
Market Cap	24M 252M
Previous open	5.99
Previous close	4.05

Technical Score

By Trading Central

Confidence

Bearish Evidence

3.17 / 3.4644 Support & Resistance

Voyager Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

24 kwi 2026, 00:00 UTC

Earnings

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

24 kwi 2026, 00:00 UTC

Earnings

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

23 kwi 2026, 23:47 UTC

Market Talk

Gold Edges Lower Amid Ongoing Concerns Over Higher Inflation -- Market Talk

23 kwi 2026, 23:43 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23 kwi 2026, 23:43 UTC

Market Talk

Global Equities Roundup: Market Talk

23 kwi 2026, 23:43 UTC

Market Talk

Nikkei May Decline Amid Uncertainty Over U.S.-Iran Conflict -- Market Talk

23 kwi 2026, 23:13 UTC

Acquisitions, Mergers, Takeovers

Trump on Spirit Airlines: 'I Think We'd Just Buy It' -- Update

23 kwi 2026, 22:33 UTC

Earnings

Intel Shares Jump 20% as AI Agents Drive Big Growth -- WSJ

23 kwi 2026, 22:17 UTC

Earnings

PLS Executed Offtake Agreement With Ronbay

23 kwi 2026, 22:17 UTC

Earnings

PLS Secured Up to A$38.1M in Australia Government ARENA Grant Funding

23 kwi 2026, 22:16 UTC

Earnings

PLS Commences Commissioning of Midstream Demonstration Plant

23 kwi 2026, 22:15 UTC

Earnings

PLS Group Reaffirms FY26 Guidance for All Metrics

23 kwi 2026, 22:14 UTC

Earnings

PLS Group 3Q Cash Margin From Operations A$461M at March 31

23 kwi 2026, 22:14 UTC

Earnings

PLS Group 3Q Cash Balance A$1.455 Billion at March 31

23 kwi 2026, 22:13 UTC

Earnings

PLS Group 3Q Unit Operating Cost A$733/Ton CIF, Up 2% on 2Q

23 kwi 2026, 22:12 UTC

Earnings

Correct: PLS Group 3Q Unit Operating Cost A$520/Ton FOB, Down 11% on 2Q

23 kwi 2026, 22:12 UTC

Earnings

PLS Group 3Q Unit Operating Cost US$520/Ton FOB, Down 11% on 2Q

23 kwi 2026, 22:11 UTC

Earnings

PLS Group 3Q Realized Price US$1,867/Ton, Up 61% on 2Q

23 kwi 2026, 22:10 UTC

Earnings

PLS Group 3Q Revenue A$567,000, Up 52% on 2Q

23 kwi 2026, 22:09 UTC

Earnings

PLS Group 3Q Sales 195,700 Tons, Down 16% on 2Q

23 kwi 2026, 22:08 UTC

Earnings

PLS Group 3Q Production 232,400 Tons, Up 12% on 2Q

23 kwi 2026, 22:04 UTC

Earnings

Intel Sales Rise 7% as AI Agents Drive Growth -- WSJ

23 kwi 2026, 21:56 UTC

Market Talk

Earnings

Intel Points to Growing Role of CPUs Amid AI Shifts -- Market Talk

23 kwi 2026, 21:48 UTC

Acquisitions, Mergers, Takeovers

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

23 kwi 2026, 21:27 UTC

Earnings

Intel CFO: All Demand Signals Point to Growing Role of CPUs in AI Era

23 kwi 2026, 21:25 UTC

Earnings

Intel CFO Expects Factories to Continue Increasing Supply in 3Q, 4Q, but at More Measured Pace Than Previously Expected

23 kwi 2026, 21:24 UTC

Earnings

SAP Stock Rebounds From Software Slaughter. The Cloud Boosted Europe's Tech Titan. -- Barrons.com

23 kwi 2026, 21:24 UTC

Earnings

Blackstone Stock Falls After Earnings. Private Credit Remains in Focus. -- Barrons.com

23 kwi 2026, 21:21 UTC

Earnings

Intel to Look for Unconventional Way to Boost Manufacturing Capacity Through Musk's Terafab Project, CEO Says

23 kwi 2026, 21:21 UTC

Earnings

Intel CEO: He, Elon Musk Believe Global Semiconductor Supply Isn't Keeping Up With Accelerating Demand

Peer Comparison

Price change

Voyager Therapeutics Inc Forecast

Price Target

By TipRanks

256.07% upside

12 Months Forecast

Average 14.67 USD 256.07%

High 25 USD

Low 8 USD

Based on 8 Wall Street analysts offering 12 month price targets forVoyager Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Voyager Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.17 / 3.4644Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.